ANHL1522,A Pilot Study of Rituximab (RTX) and Third Party Latent Membrane Protein (LMP)-specific Cytotoxic T-Lymphocytes (LMP-TC, IND # 17068) in Pediatric Solid Organ Recipients (SOT) with EBV-Positive CD20-Positive Post-Transplant Lymphoproliferative Disease (PTLD)
Study ID: STU 032017-108
Summary
This is a pilot study of Rituximab (RTX) with or without Third Party Latent Membrane Protein (LMP)-specific Cytotoxic T-Lymphocytes (LMP-specific T cells or LMP-TC) in pediatric and young adult solid organ transplant recipients (SoT) with newly diagnosed eBV-Positive CD20-Positive Post-Transplant Lymphoproliferative Disease (PTLD).